

Hemochromatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/HFD7CF83C304EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: HFD7CF83C304EN

Abstracts

The 7 major hemochromatosis markets are expected to exhibit a CAGR of 6.3% during 2024-2034.

The hemochromatosis market has been comprehensively analyzed in IMARC's new report titled "Hemochromatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemochromatosis refers to a hereditary disorder characterized by the excessive accumulation of iron in the body. This condition disrupts the body's ability to regulate iron absorption, leading to its buildup in various organs such as the liver, heart, and pancreas. Common symptoms of the ailment include fatigue, joint pain, abdominal pain, and an overall sense of weakness. Individuals suffering from this disorder might also experience changes in skin pigmentation, specifically a bronze or grayish hue, often referred to as bronze diabetes. The diagnosis of hemochromatosis typically involves a combination of clinical evaluation, medical history, and physical examination. The healthcare professional might also conduct blood tests to measure serum ferritin and transferrin saturation levels and genetic testing to identify specific mutations associated with the disorder, particularly the HFE gene mutations. They may further perform imaging studies like magnetic resonance imaging (MRI) or liver biopsies to assess the extent of iron accumulation in organs.

The escalating instances of genetic mutations affecting the HFE gene, resulting in excessive iron accumulation within various organs of the body, are primarily driving the hemochromatosis market. In addition to this, the inflating utilization of supportive therapies like nutritional counseling and lifestyle modifications to manage symptoms and enhance overall well-being is also creating a positive outlook for the market.

Moreover, the widespread adoption of advanced molecular diagnostics, which offer improved specificity and sensitivity in detecting genetic mutations associated with the condition, is further bolstering the market growth. Apart from this, the rising usage of precision medicine, since it tailors treatment strategies based on an individual patient's genetic makeup and disease characteristics, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of effective therapeutic interventions, such as phlebotomy and iron-chelating agents, owing to their several advantages, like reducing excess iron levels, protecting vital organs, and improving the quality of life for people suffering from the illness, is also augmenting the market growth. Furthermore, the increasing demand for gene editing technologies, including CRISPR-Cas9, which hold the promise of directly correcting or replacing the mutated genes responsible for the disorder, is expected to drive the hemochromatosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hemochromatosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemochromatosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemochromatosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the hemochromatosis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the hemochromatosis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hemochromatosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the hemochromatosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the hemochromatosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the hemochromatosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of hemochromatosis across the seven major markets?

What is the number of prevalent cases (2018-2034) of hemochromatosis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of hemochromatosis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with hemochromatosis across the seven major markets?

What is the size of the hemochromatosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of hemochromatosis?

What will be the growth rate of patients across the seven major markets?

Hemochromatosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for hemochromatosis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hemochromatosis market?

What are the key regulatory events related to the hemochromatosis market?

What is the structure of clinical trial landscape by status related to the hemochromatosis market?

What is the structure of clinical trial landscape by phase related to the hemochromatosis market?

What is the structure of clinical trial landscape by route of administration related to the hemochromatosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 HEMOCHROMATOSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 HEMOCHROMATOSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 HEMOCHROMATOSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (???2018-2034)
 - 7.2.4 Epidemiology by Gender (???2018-2034)
 - 7.2.5 Diagnosed Cases (???2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (???2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (???2018-2034)
 - 7.3.4 Epidemiology by Gender (???2018-2034)
 - 7.3.5 Diagnosed Cases (???2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (???2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (???2018-2034)
 - 7.4.4 Epidemiology by Gender (???2018-2034)
 - 7.4.5 Diagnosed Cases (???2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (???2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (???2018-2034)
 - 7.5.4 Epidemiology by Gender (???2018-2034)
 - 7.5.5 Diagnosed Cases (???2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (???2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (???2018-2034)
 - 7.6.4 Epidemiology by Gender (???2018-2034)
 - 7.6.5 Diagnosed Cases (???2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (???2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (???2018-2034)

- 7.7.4 Epidemiology by Gender (???2018-2034)
- 7.7.5 Diagnosed Cases (???2018-2034)
- 7.7.6 Patient Pool/Treated Cases (???2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (???2018-2034)
 - 7.8.4 Epidemiology by Gender (???2018-2034)
 - 7.8.5 Diagnosed Cases (???2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (???2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (???2018-2034)
 - 7.9.4 Epidemiology by Gender (???2018-2034)
 - 7.9.5 Diagnosed Cases (???2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (???2018-2034)

8 HEMOCHROMATOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 HEMOCHROMATOSIS - UNMET NEEDS

10 HEMOCHROMATOSIS - KEY ENDPOINTS OF TREATMENT

11 HEMOCHROMATOSIS - MARKETED PRODUCTS

- 11.1 List of Hemochromatosis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 HEMOCHROMATOSIS - PIPELINE DRUGS

12.1 List of Hemochromatosis Pipeline Drugs Across the Top 7 Markets

12.1.1 LJPC401 - La Jolla Pharmaceutical

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 PTG-300 - Protagonist Therapeutics

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. HEMOCHROMATOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. HEMOCHROMATOSIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 HEMOCHROMATOSIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Hemochromatosis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Hemochromatosis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

- 15.3.1 Hemochromatosis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Hemochromatosis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Hemochromatosis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Hemochromatosis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Hemochromatosis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Hemochromatosis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Hemochromatosis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Hemochromatosis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Hemochromatosis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Hemochromatosis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Hemochromatosis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Hemochromatosis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Hemochromatosis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Hemochromatosis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Hemochromatosis - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Hemochromatosis - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Hemochromatosis - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Hemochromatosis - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Hemochromatosis - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Hemochromatosis - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Hemochromatosis - Access and Reimbursement Overview

16 HEMOCHROMATOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 HEMOCHROMATOSIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 HEMOCHROMATOSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Hemochromatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/HFD7CF83C304EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HFD7CF83C304EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

